Stockreport

DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants

DiaMedica Therapeutics Inc.  (DMAC) 
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm Check Earnings Report
PDF Favorable DM199 safety profile across tested dosesPharmacodynamic results helped identify dose range for Phase II studiesEncouraging early signals in mechanism biomarker [Read more]